JP2006503106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503106A5 JP2006503106A5 JP2004568902A JP2004568902A JP2006503106A5 JP 2006503106 A5 JP2006503106 A5 JP 2006503106A5 JP 2004568902 A JP2004568902 A JP 2004568902A JP 2004568902 A JP2004568902 A JP 2004568902A JP 2006503106 A5 JP2006503106 A5 JP 2006503106A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- disease
- mental
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 208000020016 psychiatric disease Diseases 0.000 claims 6
- 208000016285 Movement disease Diseases 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 206010012335 Dependence Diseases 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 206010034912 Phobia Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 239000003176 neuroleptic agent Substances 0.000 claims 3
- 230000000701 neuroleptic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- -1 4-benzo [d] isothiazol-3-yl-piperazin-1-yl Chemical group 0.000 claims 2
- DGXZSCUMGGWVBR-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=C(Cl)C(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 DGXZSCUMGGWVBR-UHFFFAOYSA-N 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 208000015238 neurotic disease Diseases 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010068631 Childhood depression Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010073211 Postural tremor Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000000552 Scott syndrome Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 201000002426 animal phobia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 206010020765 hypersomnia Diseases 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41147502P | 2002-09-17 | 2002-09-17 | |
| US41635502P | 2002-10-04 | 2002-10-04 | |
| PCT/IB2003/003902 WO2004026864A1 (en) | 2002-09-17 | 2003-09-05 | Heterocyclic substituted piperazines for the treatment of schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503106A JP2006503106A (ja) | 2006-01-26 |
| JP2006503106A5 true JP2006503106A5 (enExample) | 2006-10-26 |
Family
ID=32033549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004568902A Pending JP2006503106A (ja) | 2002-09-17 | 2003-09-05 | 統合失調症を処置するためのヘテロ環式置換ピペラジン |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040138230A1 (enExample) |
| EP (1) | EP1546143A1 (enExample) |
| JP (1) | JP2006503106A (enExample) |
| KR (1) | KR20050057404A (enExample) |
| AP (1) | AP2005003250A0 (enExample) |
| AR (1) | AR041260A1 (enExample) |
| AU (1) | AU2003263413A1 (enExample) |
| BR (1) | BR0314393A (enExample) |
| CA (1) | CA2499326A1 (enExample) |
| CO (1) | CO5550472A2 (enExample) |
| EA (1) | EA200500342A1 (enExample) |
| EC (1) | ECSP055676A (enExample) |
| HR (1) | HRP20050248A2 (enExample) |
| IS (1) | IS7710A (enExample) |
| MA (1) | MA27438A1 (enExample) |
| MX (1) | MXPA05002007A (enExample) |
| NO (1) | NO20051826L (enExample) |
| OA (1) | OA12923A (enExample) |
| PA (1) | PA8582601A1 (enExample) |
| PE (1) | PE20050132A1 (enExample) |
| PL (1) | PL375981A1 (enExample) |
| RS (1) | RS20050195A (enExample) |
| TW (1) | TW200409771A (enExample) |
| UY (1) | UY27976A1 (enExample) |
| WO (1) | WO2004026864A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505397A1 (en) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
| BRPI0416739A (pt) * | 2003-12-08 | 2007-01-16 | Warner Lambert Co | derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia |
| MXPA06007654A (es) * | 2003-12-31 | 2006-09-04 | Warner Lambert Co | Derivados de piperidina n-sustituidos. |
| US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| WO2008015516A1 (en) * | 2006-07-28 | 2008-02-07 | Pfizer Products Inc. | Fused tricyclic heterocycles for the treatment of schizophrenia |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| RU2497819C2 (ru) * | 2007-05-21 | 2013-11-10 | Ривайва Фармасьютикалс, Инк. | Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина |
| CA2723775A1 (en) | 2008-05-08 | 2009-11-12 | Allergan, Inc. | Therapeutically useful substituted 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline compounds |
| US20090281322A1 (en) * | 2008-05-08 | 2009-11-12 | Allergan, Inc. | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
| JP2011529090A (ja) * | 2008-07-28 | 2011-12-01 | 江蘇国華投資有限公司 | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 |
| CN102159557A (zh) | 2008-09-22 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 哌嗪d3和5-ht2a受体调节剂 |
| CA2736724A1 (en) * | 2008-09-23 | 2010-04-01 | F.Hoffmann-La Roche Ag | Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
| AU2014265021B2 (en) * | 2009-06-25 | 2016-07-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| PT2445502T (pt) * | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ |
| TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之ｐｂｋ抑制劑 |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| ES2601457T3 (es) | 2011-07-28 | 2017-02-15 | Otsuka Pharmaceutical Co., Ltd. | Método para producir compuestos de benzo[b]tiofeno |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| JP5714152B2 (ja) * | 2014-03-26 | 2015-05-07 | 江蘇恒誼薬業有限公司 | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 |
| CN106608875A (zh) * | 2015-10-26 | 2017-05-03 | 江苏恩华药业股份有限公司 | 一种稠和杂环类衍生物合成及其应用 |
| CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| JPWO2020230802A1 (enExample) * | 2019-05-14 | 2020-11-19 | ||
| WO2021098737A1 (zh) * | 2019-11-18 | 2021-05-27 | 上海枢境生物科技有限公司 | 稠和杂环类衍生物及其应用 |
| EP4382521A4 (en) * | 2021-08-05 | 2025-01-01 | Shujing Biopharma Co., Ltd | Regulator containing tricyclic derivative, preparation method therefor and application thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3706427A1 (de) * | 1987-02-27 | 1988-09-08 | Boehringer Mannheim Gmbh | Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel |
| GB8723763D0 (en) * | 1987-10-09 | 1987-11-11 | Hydro Tech Ltd | Liquid flow control device |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| JP2768981B2 (ja) * | 1989-06-22 | 1998-06-25 | シャープ株式会社 | 光メモリ素子 |
| WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
| US5143923B1 (en) * | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
| MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| TW300219B (enExample) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| DE19746612A1 (de) * | 1997-10-22 | 1999-04-29 | Basf Ag | 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| HK1047582B (zh) * | 1999-06-23 | 2005-03-04 | 萨诺费－阿文蒂斯德国有限公司 | 取代的苯並咪唑 |
-
2003
- 2003-09-05 EA EA200500342A patent/EA200500342A1/ru unknown
- 2003-09-05 EP EP03797433A patent/EP1546143A1/en not_active Withdrawn
- 2003-09-05 JP JP2004568902A patent/JP2006503106A/ja active Pending
- 2003-09-05 PL PL03375981A patent/PL375981A1/xx not_active Application Discontinuation
- 2003-09-05 BR BR0314393-7A patent/BR0314393A/pt not_active IP Right Cessation
- 2003-09-05 AU AU2003263413A patent/AU2003263413A1/en not_active Abandoned
- 2003-09-05 CA CA002499326A patent/CA2499326A1/en not_active Abandoned
- 2003-09-05 MX MXPA05002007A patent/MXPA05002007A/es unknown
- 2003-09-05 WO PCT/IB2003/003902 patent/WO2004026864A1/en not_active Ceased
- 2003-09-05 OA OA1200500072A patent/OA12923A/en unknown
- 2003-09-05 HR HR20050248A patent/HRP20050248A2/hr not_active Application Discontinuation
- 2003-09-05 KR KR1020057004592A patent/KR20050057404A/ko not_active Abandoned
- 2003-09-05 AP AP2005003250A patent/AP2005003250A0/xx unknown
- 2003-09-05 RS YUP-2005/0195A patent/RS20050195A/sr unknown
- 2003-09-12 PE PE2003000930A patent/PE20050132A1/es not_active Application Discontinuation
- 2003-09-12 US US10/660,908 patent/US20040138230A1/en not_active Abandoned
- 2003-09-15 AR ARP030103336A patent/AR041260A1/es unknown
- 2003-09-15 UY UY27976A patent/UY27976A1/es not_active Application Discontinuation
- 2003-09-15 PA PA20038582601A patent/PA8582601A1/es unknown
- 2003-09-16 TW TW092125508A patent/TW200409771A/zh unknown
-
2005
- 2005-02-24 IS IS7710A patent/IS7710A/is unknown
- 2005-03-15 EC EC2005005676A patent/ECSP055676A/es unknown
- 2005-03-17 MA MA28152A patent/MA27438A1/fr unknown
- 2005-03-18 CO CO05025665A patent/CO5550472A2/es not_active Application Discontinuation
- 2005-04-15 NO NO20051826A patent/NO20051826L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005521723A5 (enExample) | ||
| CA2538915A1 (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| TWI301760B (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
| AU2006283359B2 (en) | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | |
| JP2020531505A5 (enExample) | ||
| US20080032998A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
| Henen et al. | [1, 2, 4] Triazolo [4, 3-a] quinoxaline: synthesis, antiviral, and antimicrobial activities | |
| JP2017081918A5 (enExample) | ||
| JP2010520263A5 (enExample) | ||
| Sollis | Short and novel stereospecific synthesis of trisubstituted 2, 5-diketopiperazines | |
| AU2021262281A1 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| JP2024542881A (ja) | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 | |
| JP2024535860A5 (enExample) | ||
| JP2024535343A5 (enExample) | ||
| CA2540247A1 (en) | Prodrugs of amino acids with affinity for the .alpha.2.delta.-protein | |
| KR102557791B1 (ko) | 키누레닌 모노옥시게나제 억제제로 유용한 3-(6-알콕시-5-클로로벤조[d]이속사졸-3-일)프로판산 | |
| ZA200502216B (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia. | |
| JP2010529080A5 (enExample) | ||
| US7550482B2 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
| US20060004001A1 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
| YU90702A (sh) | S-metil-dihidro-ziprasidon za lečenje psihijatrijskih i okularnih oboljenja | |
| US20070060585A1 (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
| JP2011513353A (ja) | ２−アミノキノリン類 | |
| JP2004529901A5 (enExample) | ||
| Sajadikhah et al. | 1, 4-Dithiane-2, 5-diol in the synthesis of thiophenes (microreview) |